Shamburg News · 8-K filed Nov 16, 2026, 4:16 PM EST

AEON Biopharma Reports Third Quarter 2026 Financial Results and Corporate Update

AEON · AEON Biopharma, Inc.

  • Earnings
  • Financial statements
  • Other event
  • Materiality: high

AEON Biopharma reported net income of $2,465 thousand, or $0.01 per basic and diluted share, for the third quarter ended September 30, 2026, compared with a net loss of $4,538 thousand a year earlier. The company reported cash and cash equivalents of $11.4 million as of September 30, 2026, and about $6.2 million in gross proceeds from milestone warrant exercises received by November 16, 2026. It expects these resources to fund operations into the second quarter of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001837607-26-000087.

Written from the filing by Shamburg Markets. Figures are as reported by the company.